Pharmaceutical Raw Material Industry Boom Creates Environmental Headache
This article was originally published in PharmAsia News
With an annual growth rate of 20 percent since 2001, China has become the biggest pharmaceutical raw material producer and exporter in the world. The country produced 1.23 million tonnes of over 1,500 raw ingredients in 2005, with some having dominant shares in the global market. For instance, China's saccharin sodium, vitamin C, and penicillin industrial salt exports accounted for 90, 65, and 60 percent of the world's trade, respectively. Even though the manufacturing of products such as penicillin salt and caffeine has been identified as highly energy-intensive and polluting, these industries are still expanding, at great environmental and health costs. Experts are calling for more stringent control of pharmaceutical raw material production and export. (Click here for more - Chinese Language)
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.